Literature DB >> 26092300

Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature.

Maja Ogielska1, Philippe Lanotte2, Cécile Le Brun2, Anne Sophie Valentin3, Denis Garot4, Anne-Charlotte Tellier5, Jean Michel Halimi6, Philippe Colombat7, Laurent Guilleminault8, Bertrand Lioger9, Hélène Vegas10, Bertrand De Toffol11, Thierry Constans12, Louis Bernard13.   

Abstract

BACKGROUND: Clostridium difficile infection (CDI) is a common cause of nosocomial diarrhoea. People in the general community are not usually considered to be at risk of CDI. CDI is associated with a high risk of morbidity and mortality. The risk of severity is defined by the Clostridium Severity Index (CSI).
METHODS: The cases of 136 adult patients with CDI treated at the University Hospital of Tours, France between 2008 and 2012 are described. This was a retrospective study.
RESULTS: Among the 136 patients included, 62 were men and 74 were women. Their median age was 64.4 years (range 18-97 years). Twenty-six of the 136 (19%) cases were community-acquired (CA) and 110 (81%) were healthcare-acquired (HCA). The major risk factors for both groups were long-term treatment with proton pump inhibitors (54% of CA, 53% of HCA patients) and antibiotic treatment within the 2.5 months preceding the CDI (50% of CA, 91% of HCA). The CSI was higher in the CA-CDI group (1.56) than in the HCA-CDI group (1.39). Intensive care was required for 8% of CA-CDI and 16.5% of HCA-CDI patients.
CONCLUSIONS: CDI can cause community-acquired diarrhoea, and CA-CDI may be more severe than HCA-CDI. Prospective studies of CDI involving people from the general community without risk factors are required to confirm this observation.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Clostridium Severity Index score; Clostridium difficile; Community infection; Proton pump inhibitors

Mesh:

Year:  2015        PMID: 26092300     DOI: 10.1016/j.ijid.2015.06.007

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  11 in total

Review 1.  Comparative pathogenesis of enteric clostridial infections in humans and animals.

Authors:  Francisco A Uzal; Mauricio A Navarro; Jihong Li; John C Freedman; Archana Shrestha; Bruce A McClane
Journal:  Anaerobe       Date:  2018-06-05       Impact factor: 3.331

2.  Distribution and risk factor analysis for Clostridium difficile-associated diarrhea among hospitalized children over one year of age.

Authors:  Chunna Zhao; Shu Guo; Xiaoyun Jia; Xiwei Xu
Journal:  Pediatr Investig       Date:  2019-10-28

3.  Role of Single Procalcitonin Test on Admission as a Biomarker for Predicting the Severity of Clostridium difficile Infection.

Authors:  Zohar Hamo; Maya Azrad; Orna Nitzan; Asaf Sagie; Linda Tkhawkho; Dana Binyamin; Avi Peretz
Journal:  Front Microbiol       Date:  2017-12-19       Impact factor: 5.640

4.  Epidemiological Features of Clostridium difficile Colonizing the Intestine of Jordanian Infants.

Authors:  Eman N Abu-Khader; Eman F Badran; Asem A Shehabi
Journal:  Int J Microbiol       Date:  2017-12-20

5.  Complete genome sequence of Peptoclostridium difficile strain Z31.

Authors:  Francisco C F Lobato; Henrique C P Figueiredo; Felipe L Pereira; Carlos A Oliveira Júnior; Rodrigo O S Silva; Fernanda A Dorella; Alex F Carvalho; Gabriel M F Almeida; Carlos A G Leal
Journal:  Gut Pathog       Date:  2016-04-01       Impact factor: 4.181

Review 6.  A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.

Authors:  Li-Yuan Yu; Lu-Ning Sun; Xue-Hui Zhang; Yue-Qi Li; Lei Yu; Zi-Qing-Yun Yuan; Ling Meng; Hong-Wen Zhang; Yong-Qing Wang
Journal:  Adv Ther       Date:  2017-04-20       Impact factor: 3.845

Review 7.  Epidemiology of community-acquired and recurrent Clostridioides difficile infection.

Authors:  Yichun Fu; Yuying Luo; Ari M Grinspan
Journal:  Therap Adv Gastroenterol       Date:  2021-05-22       Impact factor: 4.409

Review 8.  Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.

Authors:  Lauren E Bloomfield; Thomas V Riley
Journal:  Infect Dis Ther       Date:  2016-07-01

9.  Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection.

Authors:  Elena A Usacheva; Lance R Peterson; Katherine Mendoza; Donna M Schora; M Moazzem Hossain; Jian-Ping Jin
Journal:  J Clin Med Res       Date:  2019-01-05

10.  Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).

Authors:  E Bouza; J M Aguado; L Alcalá; B Almirante; P Alonso-Fernández; M Borges; J Cobo; J Guardiola; J P Horcajada; E Maseda; J Mensa; N Merchante; P Muñoz; J L Pérez Sáenz; M Pujol; E Reigadas; M Salavert; J Barberán
Journal:  Rev Esp Quimioter       Date:  2020-02-20       Impact factor: 1.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.